

Thursday 29 June – morning session

08.30 Registration opens

Opening plenary

10.00 Welcome by Michelle Mitchell, Chief Executive, MS Society

10.15 What MS research can learn from other disorders – *J Gallacher*

Parallel sessions

Comprehensive care and symptom management

11.20 Maintaining paid work in MS – *H Ford*

11.40 MS fatigue: what can cross-sectional comparison studies tell us about the underpinning neurophysiology? – *J Saxton*

12.00 Abdominal massage for neurogenic bowel dysfunction in people with MS (AMBER – Abdominal Massage for Bowel Dysfunction) – *D McClurg*

12.15 Barriers and Solutions to Participation in Exercise for People with MS: A Consensus Study Using Nominal Group technique – *F Moffat*

12.30 THC:CBD (Nabiximols) has a beneficial effect on MS related spasticity and delays the need for intrathecal baclofen – *S De Trane*

12.45 Experiences of family and carers: SNOFLAC-MS Study – *C Bulley*

Immunopathology

11.20 MS from an energy perspective – *K Smith*

11.40 New insights into disease progression in MS – *C Linington*

12.00 Inflammasomes are expressed in murine CNS lesions and inflammasome products IL-1 β and IL-18 promote myelin production *in vitro* – *Y Dombrowski*

12.15 Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS): results of a phase 2 trial of mesenchymal cell therapy – *R Ali*

12.30 Active Vitamin D modulates the migratory capability of CD46 activated CD4+ T cells – *J Killick*

12.45 PD1 inhibits CD8+CD57+T-cell response to EBV and is highly expressed on CD8+CD57+T cells in people with MS – *M T Cencioni*

Thursday 29 June – afternoon session

Lunch

13.00 Workshop: How involving patients makes for better research

Parallel sessions

Neurodegeneration and myelin repair

14.05 Investigation of the role of regulatory T cells in oligodendrocyte differentiation, myelination and remyelination – *D Fitzgerald*

14.25 Modelling and manipulating myelin repair – *A Williams*

14.45 Interventions to overcome the age-related decline in CNS remyelination – *B Neumann*

15.00 Pharmacological targeting of the Nrp1/Sema3A interaction to promote remyelination in MS – *R Felici*

15.15 Proper brain function requires lifelong production of oligodendrocytes – *S Jaekel*

15.30 Understanding cybernetic principles of gene-network regulation during oligodendrogenesis – *T Ghosh*

Prescribing and patient choice

14.05 Algorithms, guidelines and dragons – *A Coles*

14.25 [Title to be confirmed] – *B Weller*

14.45 Quality-adjusted life-years from the perspective of people with MS – *E Goodwin*

15.00 Exploring influences on disease modifying therapy prescribing rates and practices across the UK – *E Cameron*

15.15 Choosing whether and when to start DMT. A new person-focused conceptual framework – *A Manzano*

15.30 Access to and use of MS Services by people with progressive MS in the UK: an online survey via the UK MS Register – *E Campbell*

16.00 Poster session

Debate

17.00 This house believes that, for MS, early treatment requires aggressive treatment

Drinks and conference dinner

18.30 Drinks reception

Welcome by *Shona Robison MSP, Cabinet Secretary for Health and Sport*

19.30 Conference dinner at [Mansfield Traquair](#)

Friday 30 June – morning session

08.30 Registration opens

Ian McDonald Memorial Award Lecture

09.30 Myelin cell biology and progressive MS – *C ffrench-Constant*
Introduction by S Chandran

10.30 Poster session

Parallel sessions

Causes and predicting prognosis	Technological innovations and self-management
11.25 Can the intrathecal inflammatory profile and cortical grey matter pathology be used as a prognostic marker in MS? – <i>R Reynolds</i>	11.20 Clinical tracking MS – <i>M Dsouza</i>
11.50 Early MRI predictors of secondary progressive disease course in relapse-onset MS – <i>W Brownlee</i>	11.40 Web-Based Physiotherapy for People with MS (WEB-PaMS); a multi-centre randomised controlled feasibility study – <i>L Paul</i>
12.15 The opportunities and challenges of a long-term clinically isolated syndrome follow-up study – <i>K Chung</i>	12.00 The use of individually tailored rehabilitation exergames: the views of people affected by MS – <i>M Taylor</i>
12.30 EBV infection empowers human B cells for autoimmunity – role of autophagy and relevance to MS – <i>E Morandi</i>	12.15 UK MS Register: initial clinical diagnosis validation – <i>R Middleton</i>
12.45 Narrowband UVB phototherapy for Clinically Isolated Syndrome: Delivering the benefits of all UVB-induced molecules – <i>P Hart</i>	12.30 Preliminary results from a randomised trial comparing FES and AFO for foot drop in MS: initial orthotic effects on speed – <i>A Lord</i>
	12.45 The effect of cycling using active-passive trainers on spasticity, cardiovascular fitness, function and quality of life in people with MS – <i>A Barclay</i>

Friday 30 June – afternoon session

Lunch

13.00 Workshop: Engaging the public with your research

Closing plenary

14.00 Current clinical trials and expectations for the not too distant future –
J Chataway

Presentations

14.45 Poster prizes and 'MS in Focus' winners announced

Optional excursions (15.00 – 18.00)

Whiskey tasting (£15 per head)
Guided experience with experts, tasting whiskies from different regions of Scotland. Includes nibbles.

Walking tour (free) of the old city and Royal Mile, with opportunities to stop off at:

- Edinburgh Castle,
- Blair Street Underground Vaults
- the Camera Obscura
- Holyrood Palace

entry fees at own cost

Exhibitors

MS Trust • Digesting Science • Shift MS • MS Society Tissue Bank • UK MS Register • Queens Square Clinical Trials Centre • Merck • Biogen • Roche • Teva • MedDay • Novartis • Sanofi Genzyme

Plus information from the MS Society on research funding, public involvement and our patient-facing information resources.

CPD credits

MS Frontiers 2017 has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 12 category 1 (external) CPD credits.